losartan has been researched along with Triple Negative Breast Neoplasms in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Q | 1 |
| He, X | 1 |
| Qin, X | 1 |
| Liu, Y | 1 |
| Jiang, H | 1 |
| Wang, J | 1 |
| Wu, S | 1 |
| Zhou, R | 1 |
| Yu, C | 1 |
| Liu, S | 1 |
| Zhang, H | 1 |
| Tian, M | 1 |
| Hu, C | 1 |
| Liu, X | 1 |
| Ran, W | 1 |
| Meng, J | 1 |
| Zhai, Y | 1 |
| Zhang, P | 1 |
| Yin, Q | 1 |
| Yu, H | 1 |
| Zhang, Z | 1 |
| Li, Y | 1 |
2 other studies available for losartan and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer.
Topics: Animals; Cell Line, Tumor; Humans; Immunotherapy; Losartan; Mice; Mice, Inbred BALB C; Triple Negati | 2022 |
Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibiotics, Antineoplastic; Cancer-Associated Fib | 2017 |